L
Laurent Greillier
Researcher at Aix-Marseille University
Publications - 222
Citations - 5588
Laurent Greillier is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 27, co-authored 149 publications receiving 3353 citations. Previous affiliations of Laurent Greillier include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
TL;DR: Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
Journal ArticleDOI
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
TL;DR: Immune Check Point inhibitors have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 ( PD-L1) inhibitors being the most studied drugs.
Journal ArticleDOI
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Thierry Jahan,Scott J. Antonia,Youssef Oulkhouir,Yolanda Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Abderrahim Oukessou,Christine Baudelet,Gérard Zalcman +20 more
TL;DR: The CheckMate 743 trial as mentioned in this paper showed that nivolumab plus ipilimumab significantly improved overall survival compared to standard-of-care chemotherapy for non-small-cell lung cancer.
Journal ArticleDOI
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel,Julien Mazieres,Laurent Greillier,Sylvie Lantuejoul,Pascal Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Florian Guisier,Thierry Urban,Catherine Ligeza-poisson,David Planchard,E. Amour,Franck Morin,Denis Moro-Sibilot,Gérard Zalcman,Didier Debieuvre,Sandrine Hiret,Jacques Cadranel,Séverine Fraboulet-Moreau,Delphine Carmier +23 more
TL;DR: This multicentre randomised, non-comparative, open-label, phase 2 trial aimed to prospectively assess the anti-PD-1 monoclonal antibody alone or in combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody in patients with malignant pleural mesothelioma.
Journal ArticleDOI
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study
Romain Corre,Laurent Greillier,Hervé Le Caer,Clarisse Audigier-Valette,N. Baize,Henri Berard,Lionel Falchero,Isabelle Monnet,Eric Dansin,Alain Vergnenegre,Marie Marcq,Chantal Decroisette,Jean-Bernard Auliac,S. Bota,R. Lamy,Bartomeu Massuti,Cécile Dujon,Maurice Pérol,Jean-Pierre Daurès,Renaud Descourt,Hervé Lena,Carine Plassot,Christos Chouaid +22 more
TL;DR: In elderly patients with advanced NSCLC, treatment allocation on the basis of CGA failed to improve the TFFS or OS but slightly reduced treatment toxicity.